Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5832281 | 0.96 | HTR6 (0.40) | HTR6HTR2AHTR2BGPR119RORC | |
| SCHEMBL5832826 | 0.89 | AGTR1 (0.41) | HTR6RORCKDM4EAKR1C3 | |
| SCHEMBL5832971 | 0.85 | POLB (0.39) | KDM2BKDM4E | |
| SCHEMBL5832868 | 0.84 | AGTR1 (0.43) | HTR6RORCKDM4EPKMAKR1C3 | |
| SCHEMBL5832745 | 0.80 | KDM4E (0.39) | HTR6GPR119KDM4E | |
| SCHEMBL5832219 | 0.80 | ALDH1A1 (0.39) | KDM4EGRM1 | |
| SCHEMBL5833319 | 0.78 | HRH3 (0.42) | — | |
| SCHEMBL5832899 | 0.78 | CDK4 (0.42) | — | |
| SCHEMBL5832239 | 0.77 | CHRNA7 (0.57) | — | |
| SCHEMBL5832425 | 0.75 | KDM4E (0.40) | GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | claimed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | claimed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | claimed |
| US-7060699-B2 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2006-06-13 | — | — | US | disclosed |
| EP-1301514-B1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | NEUROSEARCH A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| EP-1301514-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176416-A1 | Aryl and heteroaryl diazabicycloalkanes, their preparation and use | CHRNA7, CHRNA5, CHRNA2 | HTR6 87/4885HTR2A 81/4885HTR2B 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.